Board and Directors

Michael Spooner

Executive Chairman

Mr Spooner was appointed as Non Executive Chairman in May 2016 and in July 2019 became Executive Chairman. Mr Spooner also serves on the Board of Directors of Mesoblast Inc.

Mr Spooner has served on the Board of Directors with several international medtech, pharma, vaccine and biotechnology companies, including MicrofluidX, BiVacor, Advanced Surgical Design & Manufacture Limited, Peplin, Inc., Hawaii Biotech, Inc., Hunter Immunology Limited, and as managing director of Ventracor Limited.

Mr Spooner has lived much of his business life internationally and has held a number of significant leadership positions including as a partner and director of consulting services for 2 of the world’s leading firms

He has a successful recored in leading corporate restructing as well as strategy design and implementation. Importantly Mr Spooner has also successfully lead partnership programs and major financing iniatives.

Dr Gary Pace

Non-Executive Director

Gary W Pace was appointed Non-Executive Director in April 2016. Dr Pace has more has more than 40 years of experience in the development and commercialization of advanced life sciences and related technologies, spanning biotechnology, pharmaceuticals, medical devices, and food industries. Dr Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees.

Dr. Pace is currently a Director of Pacira Pharmaceuticals Inc (NASDAQ: PCRX);and Antisense Therapeutics (ASX: ANP) as well as several private companies.

Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology.

Damien Haakman

Non-Executive Director

Mr Haakman was appointed Non-Executive Director in 2018.

Mr Haakman is the Managing Director of a private family office. He manages a portfolio including commercial property, property development joint ventures, mezzanine finance and bridging loans as well as investments in start-up and pre-listed companies.

Damien's background includes; due diligence work, forecasting, market assumptions and trends. He has a keen interest and is following the growing wearable technology space as well as Connected Devices (Internet of Things (IoT), Smart Devices, Mobile Apps.

Dr Herbert Trachsler

Non-Executive Director

Dr Tracshler was appointed Non-Executive Director in March 2021 He practices business law as an attorney in Zurich, Switzerland, with a special focus on foreign-based enterprises with operations in Switzerland. Within the framework of his activities as an attorney at law, he serves as a member of the Board of Directors for the Swiss entities of multinational groups. His clients are operative in all relevant industrial sectors, as well as in financial businesses. As a pro-bono activity, Herbert was a member of the Board of Trustees of ‘The King Albert I Memorial Foundation’ for more than ten years. Currently, he is a member of the Committee of ‘Against Malaria (Switzerland)’.

Dr Paolo Bavaj

Non-Executive Director

Dr Bavaj was appointed Non-Executive Director in April 2022.

Dr Bavaj is the head of Henkel Corporate Venturing, Adhesives and is a member of the Henkel Adhesive Technologies Innovation Executive Committee. He responsible for driving the development of disruptive technologies through collaboration and corporate venture investments.

Corbett Wallace

Board Advisor

Mr Wallace was appointed Board Advisor in April 2022. Mr Wallace serves as the Corporate Vice President - Product Development & Innovation of Henkel and is on the Henkel executive team.

He Specialises in Consumer Goods, Adhesive packaging and labelling, Adhesive technologies, Innovation, Sustainability, Supply security and transparency, Food safety and Consumer experience